OSLO, Norway, Aug. 29, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that it will host a R&D Day in
Oslo on Tuesday, 17 September 2019 from 9:30am to 12:30pm CEST. The programme will
include presentations from three external experts and by Nordic
Nanovector's senior management team. An update on the median
Duration of Response (mDoR) of Betalutin® treatment in the LYMRIT
37-01 trial will also be given during the day.
Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250
Oslo
Meeting Room: Auditorium
To register to attend, please e-mail ir@nordicnanovector.com by
13 September 2019.
The R&D Day will be recorded as a webcast and will be
available at www.nordicnanovector.com in the section: Investors
& Media.
The presentations will be available at www.nordicnanovector.com
in the section: Investors & Media/Reports and
Presentation/2019.
The preliminary programme is as follows;
09.30-09.50 Nordic Nanovector's pipeline – Strategic
insights Eduardo Bravo, CEO
09.50-10.10 Radioimmunotherapy – Preclinical results with
Betalutin® and comparison of alpha and beta emitters Dr
Jean-Pierre Pouget*
10.10-10.40 Future vision for R&D at Nordic
Nanovector Dr Jostein Dahle, CSO
10:40-10:50 Introduction to clinical sessions Dr Lisa
Rojkjaer, CMO
10.50-11.20 Unmet medical needs and therapeutic landscape
for recurrent follicular and marginal zone lymphoma Prof. Pier
Luigi Zinzani*
11:20-11:30 Coffee Break
11.30-12:00 Novel biologic combinations with
Betalutin® Dr Arne Kolstad*
12.00-12.20 BLA readiness: CMC commercial plans Dr
Marco Renoldi, COO
12.20-12.30 Q&A
*The external experts' speakers are:
- Dr J.P. Pouget, PhD,
Radiobiology and targeted radiotherapy group Montpellier Cancer
Research Institute (IRCM), French National Institute of Health and
Medical Research (INSERM).
- Prof. P. L. Zinzani, Professor of Hematology, Institute of
Hematology "L. e A. Seràgnoli", University of Bologna.
- Dr A. Kolstad MD, PhD, senior
consultant in Medical Oncology and Radiation Therapy, Dept of
Oncology Oslo University Hospital, The
Norwegian Radium Hospital.
For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. This information is subject to a duty
of disclosure pursuant to Section 5-12 of the Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-r-d-day-in-oslo-and-webcast,c2890940